Enhanced hemodynamic response to [D-ala2,D-Met5]-methionine enkephalin (DAME) in streptozotocin-induced diabetic rats is reversed by insulin replacement

Life Sciences

Volumn 62, Issue 24, 1998, Pages 2219-2229

  Severson, K ^a   Tackett, R L ^a  

^a NONE

Author keywords

DAME; Diabetes; Hemodynamics; Opioids; Strcptozotocin

Indexed keywords

GLUCOSE; HEXAMETHONIUM; INSULIN; METENKEPHALIN[2 DEXTRO ALANINE]; MU OPIATE RECEPTOR; NALOXONE; SODIUM CHLORIDE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC GANGLION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LEG BLOOD FLOW; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; VASCULAR RESISTANCE;

ANIMALS; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, METHIONINE; GANGLIONIC BLOCKERS; HEXAMETHONIUM; HINDLIMB; INSULIN; MALE; NALOXONE; NARCOTIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE;

ANIMALIA;

EID: 0032496119     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00200-8     Document Type: Article

References (27)

1. 1. L.J. FORMAN, S. ESTILOW, M. LEWIS, and P. VASILENKO, Diabetes 35 1309-1313 (1986).
2. 2. K. TIMMERS, N.R. VOYLES, S. ZALENSKI, S. WILKINS, and L. RECANT, Diabetes 35 1143-1151 (1986).
3. 3. A.R. CRISTLIEB, Am. J. Cardiol. 32 592-606 (1973).
4. 4. M. EPSTEIN and J.R. SOWERS, Hypertens. 19 403-418 (1992).
5. 5. J.R. HAYWOOD, RA SHAFFER, C. FASTENOW, G.D. FINK, and M.J. BRODY, Am. J. 'Physiol. 241 H237-H278 (1981).
6. 6. G. FEUERSTEIN and A.L. SIREN, Circ. 75 125-129 (1987).
7. 7. F.J. DIEZ-GUERRA, S. AUGOOD, P.C. EMSON, and R.G. DYER, Exp. Brain Res. 66 378-384 (1987).
8. 8. W.R. DIXON and A.P. CHANG, Ann. NY Acad. Sci. 604 152-160 (1990).
9. 9. W. ABEBE, K.H. HARRIS, and K.M. MACLEOD, J. Cardiovasc. Pharmacol. 16 239-248 (1990).
10. 10. R.A. COHEN, B. TESFAMARIAM, R.M. WEISBROD, and K.M. ZITNAY, Am. J. Physiol. 259 H55-H61 (1990).
11. 11. A.L. SIREN and G. FEUERSTEIN, Neuropharmacol. 30 143-152 (1991).
12. 12. J.W. HOLADAY, Annu. Rev. Pharmacol. Toxicol. 23 541-594 (1983).
13. 13. K. SCHAZ, G. STOCK, W. SIMON, K. SCHLOR, T. UNGER, R. ROCKHOLD, and D. GANTEN, Hypertens. 2 395-407 (1980).
14. 14. J. L. CAFFREY, H. GU, B.A. BARRON, and J.F. GUAGL, Am. J. Physiol. 260 H386-H392 (1991).
15. 15. M.P. OWEN and G.O. CARRIER, Proc. West. Pharmacol. Soc. 22 363-366 (1979).
16. 16. M.J. BRODY and R.L. DIXON, Circ. Res. 14 494-501 (1964).
17. 17. C. VENTURA, L. BASTAGLI, P. BERNARDI, C.M. CALDERERA, and C. GUARNIERI, Biomed. Biophys. ACTA. 987 69-74 (1989).
18. 18. K. MATSUMURA, A. ISOA, T. MITSUHIRO, T. TAKUYA, K. KAZUO and F. MASATOSHI, Hypertens. 19 648-652 (1991).
19. 19. P.J. EULIE, H.M. RHEE, and M.H. LAUGHLIN, Eur. J. Pharmacol. 137 25-31 (1987).
20. 20. J.M. WIGHTMAN, J.C. SCHADT, and R.R. GADDIS, J. Pharmacol. Exp. Ther. 241 314-320 (1987).
21. 21. D.A. BARBER and R.L. TACKETT, FASEB 6A 970 (1992).
22. 22. L.M. RESNICK, Am. J. Hypertens. 6 123S-143S (1993).
23. 23. D.A. BARBER and R.L. TACKETT, FASEB 7 A-49 (1993).
24. 24. R.P. TOWNSEND, R. YAMOMATO, M. NICKOLS, D.S. DIPATE and G.A. NICKOLS, Hypertens. Supp. 11 105-110 (1992).
25. 25. M.A. YANAGISANA, H. ITO, and T. SUGIMOTO, Circ. 81 1654-1659 (1990).
26. 26. C. LIU and R.L. TACKETT, FASEB 3A 11-97 (1989).
27. 27. J.F. BAK, U.K. JACOBSEN, F.S. JORGENSEN and O. PEDERSEN, J. Clin. Endocrinol. Metab. 69 158-164 (1989).